Hao Liu

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Hussein H. Khachfe · 2 shared papers, 2023 · strength 0.31
   • Paper The use of angiotensin system inhibitors correlates with longer survival in resected pancreatic adenocarcinoma patients. DOI 10.1016/j.hpb.2022.12.002↗
   • Paper No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borde… DOI 10.1016/j.hpb.2023.01.016↗
2. Amer H. Zureikat · 2 shared papers, 2023 · strength 0.31
   • Paper The use of angiotensin system inhibitors correlates with longer survival in resected pancreatic adenocarcinoma patients. DOI 10.1016/j.hpb.2022.12.002↗
   • Paper No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borde… DOI 10.1016/j.hpb.2023.01.016↗
3. Samer S. AlMasri · 2 shared papers, 2023 · strength 0.31
   • Paper The use of angiotensin system inhibitors correlates with longer survival in resected pancreatic adenocarcinoma patients. DOI 10.1016/j.hpb.2022.12.002↗
   • Paper No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borde… DOI 10.1016/j.hpb.2023.01.016↗
4. Nathan Bahary · 2 shared papers, 2023 · strength 0.31
   • Paper The use of angiotensin system inhibitors correlates with longer survival in resected pancreatic adenocarcinoma patients. DOI 10.1016/j.hpb.2022.12.002↗
   • Paper No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borde… DOI 10.1016/j.hpb.2023.01.016↗
5. Aatur Dilip Singhi · 2 shared papers, 2023 · strength 0.31
   • Paper The use of angiotensin system inhibitors correlates with longer survival in resected pancreatic adenocarcinoma patients. DOI 10.1016/j.hpb.2022.12.002↗
   • Paper No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borde… DOI 10.1016/j.hpb.2023.01.016↗
6. Alessandro Paniccia · 2 shared papers, 2023 · strength 0.31
   • Paper The use of angiotensin system inhibitors correlates with longer survival in resected pancreatic adenocarcinoma patients. DOI 10.1016/j.hpb.2022.12.002↗
   • Paper No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borde… DOI 10.1016/j.hpb.2023.01.016↗
7. Ibrahim Nassour · 1 shared paper, 2023 · strength 0.16
   • Paper The use of angiotensin system inhibitors correlates with longer survival in resected pancreatic adenocarcinoma patients. DOI 10.1016/j.hpb.2022.12.002↗
8. Caroline J. Rieser · 1 shared paper, 2023 · strength 0.15
   • Paper No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borde… DOI 10.1016/j.hpb.2023.01.016↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.